Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gynecology

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 149 articles: HTML format

Single Articles

July 2024
1. GILHAM C, Nedjai B, Scibior-Bentkowska D, Reuter C, et al
   Long-term prediction by DNA methylation of high-grade cervical intraepithelial neoplasia: Results of the ARTISTIC cohort.
   Int J Cancer. 2024;155:81-92.
   PubMed     Abstract available
   
   
   May 2024
2. HANSEN BT, Nygard M, Castle PE, Burger EA, et al
   Sociodemographic characteristics associated with cervical cancer screening participation by send-to-all and opt-in HPV self-sampling: Who benefits? Results from a randomized controlled trial among long-term non-attending women in Norway.
   Int J Cancer. 2024 May 15. doi: 10.1002/ijc.34989.
   PubMed     Abstract available
   
   
   
3. ILLAH O, Scott M, Redl E, Barrett JE, et al
   High performance of the DNA methylation-based WID-qEC test for detecting uterine cancers independent of sampling modalities.
   Int J Cancer. 2024 May 13. doi: 10.1002/ijc.35000.
   PubMed     Abstract available
   
   
   
4. ROSTAMI S, Rounge TB, Pestarino L, Lyle R, et al
   Differential levels of circulating RNAs prior to endometrial cancer diagnosis.
   Int J Cancer. 2024 May 11. doi: 10.1002/ijc.34951.
   PubMed     Abstract available
   
   
   
5. HUANG C, Bu H, Wang Y, Chu R, et al
   Association between coffee and tea consumption and ovarian cancer incidence: A prospective analysis in the PLCO dataset.
   Int J Cancer. 2024 May 11. doi: 10.1002/ijc.34982.
   PubMed     Abstract available
   
   
   
6. TAGUCHI A, Kato K, Furusawa A, Hara K, et al
   Heterogeneous treatment effect of dose-dense paclitaxel plus carboplatin therapy for advanced ovarian cancer.
   Int J Cancer. 2024 May 7. doi: 10.1002/ijc.34996.
   PubMed     Abstract available
   
   
   
7. FROMHAGE G, Obermayr E, Bednarz-Knoll N, Van Gorp T, et al
   Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
   Int J Cancer. 2024 May 6. doi: 10.1002/ijc.34976.
   PubMed     Abstract available
   
   
   
8. KITAHARA CM, Surcel HM, Falk R, Pfeiffer RM, et al
   Early-pregnancy sex steroid and thyroid function hormones, thyroid autoimmunity, and maternal papillary thyroid cancer incidence in the Finnish Maternity Cohort.
   Int J Cancer. 2024 May 2. doi: 10.1002/ijc.34974.
   PubMed     Abstract available
   
   
   April 2024
9. OBERMAYR E, Mohr T, Schuster E, Braicu EI, et al
   Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
   Int J Cancer. 2024 Apr 27. doi: 10.1002/ijc.34978.
   PubMed     Abstract available
   
   
   
10. DOWNHAM L, Rol ML, Forestier M, Romero P, et al
    Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34953.
    PubMed     Abstract available
    
    
    
11. SINGINI MG, Muchengeti M, Sitas F, Chen WC, et al
    Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34919.
    PubMed     Abstract available
    
    
    March 2024
12. DUUS AH, Hannibal CG, Baandrup L, Zheng G, et al
    Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer: The Extreme study.
    Int J Cancer. 2024 Mar 26. doi: 10.1002/ijc.34936.
    PubMed     Abstract available
    
    
    
13. PORTNOY A, Pedersen K, Sy S, Trope A, et al
    Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
    Int J Cancer. 2024;154:1073-1081.
    PubMed     Abstract available
    
    
    
14. LI N, Yi H, Sun W, Sundquist J, et al
    Revealing genes associated with cervical cancer in distinct immune cells: A comprehensive Mendelian randomization analysis.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34911.
    PubMed     Abstract available
    
    
    
15. HOLY P, Hlavac V, Seborova K, Susova S, et al
    Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34908.
    PubMed     Abstract available
    
    
    
16. STERPETTI AV, Gabriele R, Iannone I, Sapienza P, et al
    Reduced adherence to cervical cancer screening. The importance of information and education for women with low education and low-income.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34907.
    PubMed    
    
    
    
17. OLTHOF EMG, Aitken CA, Siebers AG, van Kemenade FJ, et al
    The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.
    Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34902.
    PubMed     Abstract available
    
    
    February 2024
18. LINDQUIST S, Frederiksen K, Petersen LK, Kjaer SK, et al
    The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
    Int J Cancer. 2024 Feb 28. doi: 10.1002/ijc.34896.
    PubMed     Abstract available
    
    
    
19. WEN TM, Xu XQ, Zhao XL, Pan CH, et al
    Efficacy and immunogenicity of AS04-HPV-16/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide.
    Int J Cancer. 2024 Feb 17. doi: 10.1002/ijc.34882.
    PubMed     Abstract available
    
    
    
20. GIZAW M, Parkin DM, Stoter O, Bukirwa P, et al
    Ovarian cancer survival in sub-Saharan Africa by human development index and histological subtypes: A population-based registry study.
    Int J Cancer. 2024 Feb 10. doi: 10.1002/ijc.34877.
    PubMed     Abstract available
    
    
    
21. TANG T, Yu H, Xu S, Zhong Y, et al
    Causal effects of endometriosis on cancer risk: A Mendelian randomization study.
    Int J Cancer. 2024 Feb 7. doi: 10.1002/ijc.34876.
    PubMed     Abstract available
    
    
    January 2024
22. AMBOREE TL, Damgacioglu H, Sonawane K, Adsul P, et al
    Recent trends in cervical cancer incidence, stage at diagnosis, and mortality according to county-level income in the United States, 2000-2019.
    Int J Cancer. 2024 Jan 25. doi: 10.1002/ijc.34860.
    PubMed     Abstract available
    
    
    
23. GIES S, Melchior P, Stroeder R, Tanzer T, et al
    Immune landscape of vulvar cancer patients treated with surgery and adjuvant radiotherapy revealed restricted T cell functionality and increased IL-17 expression associated with cancer relapse.
    Int J Cancer. 2024;154:343-358.
    PubMed     Abstract available
    
    
    
24. WANG X, Sun J, Liu Y, Lin Z, et al
    Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma.
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34844.
    PubMed     Abstract available
    
    
    
25. LEHTINEN M, Bruni L, Elfstrom M, Gray P, et al
    Scientific approaches toward improving cervical cancer elimination strategies.
    Int J Cancer. 2024 Jan 9. doi: 10.1002/ijc.34839.
    PubMed     Abstract available
    
    
    
26. EL-ZEIN M, Cheishvili D, Szyf M, Franco EL, et al
    Validation of novel DNA methylation markers in cervical precancer and cancer.
    Int J Cancer. 2024;154:104-113.
    PubMed     Abstract available
    
    
    December 2023
27. LUO J, Hendryx M, Rohan TE, Saquib N, et al
    Hysterectomy, oophorectomy and risk of non-Hodgkin's lymphoma.
    Int J Cancer. 2023 Dec 19. doi: 10.1002/ijc.34820.
    PubMed     Abstract available
    
    
    
28. 
    Harald zur Hausen 1936-2023.
    Int J Cancer. 2023;153:1937-1939.
    PubMed    
    
    
    
29. DICK S, Heideman DAM, Mom CH, Meijer CJLM, et al
    Methylation testing for the detection of recurrent cervical intraepithelial neoplasia.
    Int J Cancer. 2023;153:2011-2018.
    PubMed     Abstract available
    
    
    November 2023
30. TULSIDAS S, Fontes F, Monteiro K, Mussa M, et al
    Cervical cancer in Mozambique: Clinical characteristics, treatment and survival of incident cases admitted to the Oncology Service of Maputo Central Hospital in 2016-2018.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34779.
    PubMed     Abstract available
    
    
    
31. BONI SP, Tenet V, Horo A, Heideman DAM, et al
    High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d'Ivoire, 2018 to 2020.
    Int J Cancer. 2023 Nov 9. doi: 10.1002/ijc.34774.
    PubMed     Abstract available
    
    
    October 2023
32. 
    Correction to "Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34775.
    PubMed    
    
    
    
33. XIA D, Xu X, Du P
    Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34785.
    PubMed    
    
    
    
34. KIM YN, Joung JG, Park E, Kim JW, et al
    Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34786.
    PubMed    
    
    
    
35. HERZOG C, Jones A, Evans I, Reisel D, et al
    Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial.
    Int J Cancer. 2023 Oct 20. doi: 10.1002/ijc.34757.
    PubMed     Abstract available
    
    
    
36. COCUZZA CE, Dhillon SK, Martinelli M, Giubbi C, et al
    Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34754.
    PubMed     Abstract available
    
    
    
37. SIRIRUNGREUNG A, Lee PC, Hu YH, Liew Z, et al
    Maternal medically diagnosed infection and antibiotic prescription during pregnancy and risk of childhood cancer: A population-based cohort study in Taiwan, 2004 to 2015.
    Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34744.
    PubMed     Abstract available
    
    
    September 2023
38. INTURRISI F, de Sanjose S, Desai KT, Dagnall C, et al
    A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.
    Int J Cancer. 2023 Sep 29. doi: 10.1002/ijc.34698.
    PubMed     Abstract available
    
    
    
39. MUNGO C, Osongo CO, Ambaka J, Omoto J, et al
    Efficacy of thermal ablation for treatment of biopsy-confirmed high-grade cervical precancer among women living with HIV in Kenya.
    Int J Cancer. 2023 Sep 15. doi: 10.1002/ijc.34737.
    PubMed     Abstract available
    
    
    
40. WANG J, Edvardsson H, Strander B, Andrae B, et al
    Long-term follow-up of cervical cancer incidence after normal cytological findings.
    Int J Cancer. 2023 Sep 11. doi: 10.1002/ijc.34723.
    PubMed     Abstract available
    
    
    
41. DHOKOTERA TG, Muchengeti M, Davidovic M, Rohner E, et al
    Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
    Int J Cancer. 2023 Sep 8. doi: 10.1002/ijc.34712.
    PubMed     Abstract available
    
    
    
42. FERNANDEZ VILLALOBOS NV, Ruffieux Y, Haas AD, Chinogurei C, et al
    Cervical precancer and cancer incidence among insured women with and without HIV in South Africa.
    Int J Cancer. 2023 Sep 2. doi: 10.1002/ijc.34707.
    PubMed     Abstract available
    
    
    August 2023
43. WHITE C, Reynolds S, Murphy K, Keegan H, et al
    Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland.
    Int J Cancer. 2023 Aug 26. doi: 10.1002/ijc.34685.
    PubMed     Abstract available
    
    
    
44. BECK AL, Uldbjerg CS, Lim YH, Coull BA, et al
    Cotinine concentrations in maternal serum and amniotic fluid during pregnancy and risk of testicular germ cell cancer in the offspring: A prospective nested case-control study.
    Int J Cancer. 2023 Aug 21. doi: 10.1002/ijc.34688.
    PubMed     Abstract available
    
    
    
45. KIM YN, Joung JG, Park E, Kim JW, et al
    Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
    Int J Cancer. 2023 Aug 21. doi: 10.1002/ijc.34696.
    PubMed     Abstract available
    
    
    
46. VOSS FO, Thuijs NB, Duin S, Ozer M, et al
    Clinical validation of methylation biomarkers for optimal detection of high-grade vulvar intraepithelial neoplasia.
    Int J Cancer. 2023;153:783-791.
    PubMed     Abstract available
    
    
    
47. HUANG J, Chan SC, Fung YC, Pang WS, et al
    Global incidence, risk factors and trends of vulvar cancer: A country-based analysis of cancer registries.
    Int J Cancer. 2023 Aug 2. doi: 10.1002/ijc.34655.
    PubMed     Abstract available
    
    
    July 2023
48. REBOLJ M, Sargent A, Njor SH, Cuschieri K, et al
    Widening the offer of human papillomavirus self-sampling to all women eligible for cervical screening: Make haste slowly.
    Int J Cancer. 2023;153:8-19.
    PubMed     Abstract available
    
    
    June 2023
49. FRANDSEN CLB, Svendsen PF, Nohr B, Viuff JH, et al
    Risk of epithelial ovarian tumors among women with polycystic ovary syndrome: A nationwide population-based cohort study.
    Int J Cancer. 2023 Jun 26. doi: 10.1002/ijc.34574.
    PubMed     Abstract available
    
    
    
50. QI L, Wang M, Jia Y, Wang Y, et al
    Impact of the COVID-19 pandemic on the hospital attendance of patients with primary cervical cancer in Heilongjiang, China.
    Int J Cancer. 2023 Jun 1. doi: 10.1002/ijc.34617.
    PubMed     Abstract available
    
    
    May 2023
51. FORTNER RT, Trewin-Nybraten CB, Paulsen T, Langseth H, et al
    Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway.
    Int J Cancer. 2023 May 25. doi: 10.1002/ijc.34576.
    PubMed     Abstract available
    
    
    
52. PESOLA F, Rebolj M, Sasieni P
    Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.
    Int J Cancer. 2023;152:2061-2068.
    PubMed     Abstract available
    
    
    April 2023
53. HAAVISTO A, Wettergren L, Lampic C, Lahteenmaki PM, et al
    Premature ovarian insufficiency and chance of pregnancy after childhood cancer: A population-based study (the Fex-Can study).
    Int J Cancer. 2023 Apr 20. doi: 10.1002/ijc.34541.
    PubMed     Abstract available
    
    
    
54. TISLER A, Nygard M, Kivite-Urtane A, Berza N, et al
    Comment on "The European response to the WHO call to eliminate cervical cancer as a public health problem".
    Int J Cancer. 2023 Apr 19. doi: 10.1002/ijc.34540.
    PubMed    
    
    
    March 2023
55. SENKUS E, Delaloge S, Domchek SM, Conte P, et al
    Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial.
    Int J Cancer. 2023 Mar 27. doi: 10.1002/ijc.34525.
    PubMed     Abstract available
    
    
    
56. CUZICK J, Adcock R, Kinney W, Castle PE, et al
    Impact of HPV testing in Opportunistic Cervical Screening: Support for Primary HPV Screening in the United States.
    Int J Cancer. 2023 Mar 22. doi: 10.1002/ijc.34519.
    PubMed     Abstract available
    
    
    
57. QIN Z, Li J, Tam B, Sinha S, et al
    Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population.
    Int J Cancer. 2023;152:1159-1173.
    PubMed     Abstract available
    
    
    
58. WEVER BMM, van den Helder R, van Splunter AP, van Gent MDJM, et al
    DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self-samples, and cervical scrapes.
    Int J Cancer. 2023 Mar 13. doi: 10.1002/ijc.34504.
    PubMed     Abstract available
    
    
    
59. SILVA R, Glennon K, Metoudi M, Moran B, et al
    Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34496.
    PubMed     Abstract available
    
    
    
60. DONG L, Nygard M, Stoer NC, Klungsoyr O, et al
    Real-World Effectiveness of Hpv Vaccination Against Cervical Neoplasia Among Birth Cohorts Ineligible for Routine Vaccination.
    Int J Cancer. 2023 Mar 3. doi: 10.1002/ijc.34489.
    PubMed     Abstract available
    
    
    
61. SIEVANEN T, Korhonen TM, Jokela T, Ahtiainen M, et al
    Systemic circulating microRNA landscape in Lynch syndrome.
    Int J Cancer. 2023;152:932-944.
    PubMed     Abstract available
    
    
    February 2023
62. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
    Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
    PubMed     Abstract available
    
    
    
63. HERZOG C, Vavourakis CD, Barrett JE, Karbon G, et al
    HPV-induced host epigenetic reprogramming is lost upon progression to high-grade cervical intraepithelial neoplasia.
    Int J Cancer. 2023 Feb 21. doi: 10.1002/ijc.34477.
    PubMed     Abstract available
    
    
    January 2023
64. RASMUSSEN CL, Thomsen LT, Baandrup L, Franzmann MB, et al
    Time trends in prevalence of p16 positivity and combined HPV/p16 positivity in a large cohort of Danish vulvar cancer patients.
    Int J Cancer. 2023 Jan 24. doi: 10.1002/ijc.34446.
    PubMed     Abstract available
    
    
    
65. CASAS-AROZAMENA C, Moiola CP, Vilar A, Bouso M, et al
    Non-Invasive Detection of Microsatellite Instability in patients with Endometrial Cancer.
    Int J Cancer. 2023 Jan 17. doi: 10.1002/ijc.34435.
    PubMed     Abstract available
    
    
    
66. HUANG RY, Huang KJ, Chen KC, Hsiao SM, et al
    Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma.
    Int J Cancer. 2023 Jan 11. doi: 10.1002/ijc.34428.
    PubMed     Abstract available
    
    
    December 2022
67. VELLE A, Pesenti C, Grassi T, Beltrame L, et al
    A comprehensive investigation of histotype-specific microRNA and their variants in stage I epithelial ovarian cancers.
    Int J Cancer. 2022 Dec 21. doi: 10.1002/ijc.34408.
    PubMed     Abstract available
    
    
    
68. BARRETT JE, Jones A, Evans I, Herzog C, et al
    The WID-EC test for the detection and risk prediction of endometrial cancer.
    Int J Cancer. 2022 Dec 19. doi: 10.1002/ijc.34406.
    PubMed     Abstract available
    
    
    
69. CABASAG CJ, Arnold M, Rutherford M, Ferlay J, et al
    Shifting incidence and survival of epithelial ovarian cancer (1995-2014): a SurvMark-2 study.
    Int J Cancer. 2022 Dec 19. doi: 10.1002/ijc.34403.
    PubMed     Abstract available
    
    
    
70. SAKAKIBARA A, Nakayama T, Uchida H, Odagiri Y, et al
    Trends and future projections of cervical cancer-related outcomes in Japan: What happens if the HPV vaccine program is not implemented?
    Int J Cancer. 2022 Dec 5. doi: 10.1002/ijc.34391.
    PubMed     Abstract available
    
    
    
71. ROBERTS JM, Machalek DA, Butler BC, Crescini J, et al
    Older women testing positive for HPV 16/18 on cervical screening and risk of high-grade cervical abnormality.
    Int J Cancer. 2022 Dec 5. doi: 10.1002/ijc.34393.
    PubMed     Abstract available
    
    
    November 2022
72. BAENA A, Mesher D, Salgado Y, Martinez S, et al
    Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen-positive women: results from the ESTAMPA study.
    Int J Cancer. 2022 Nov 30. doi: 10.1002/ijc.34384.
    PubMed     Abstract available
    
    
    
73. WANG Z, Phillips LS, Rohan TE, Ho GY, et al
    Diabetes, Metformin Use, and Risk of Non-Hodgkin's Lymphoma in Postmenopausal Women: A Prospective Cohort Analysis in the Women's Health Initiative.
    Int J Cancer. 2022 Nov 28. doi: 10.1002/ijc.34376.
    PubMed     Abstract available
    
    
    
74. GOTTSCHLICH A, Payne BA, Trawin J, Albert A, et al
    Experiences with thermal ablation for cervical pre-cancer treatment after self-collection HPV-based screening in the ASPIRE Mayuge randomized trial.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34369.
    PubMed     Abstract available
    
    
    
75. KOBAYASHI R, Kawabata-Iwakawa R, Sugiyama M, Oyama T, et al
    Multiplexed genome editing by in vivo electroporation of Cas9 ribonucleoproteins effectively induces endometrial carcinoma in mice.
    Int J Cancer. 2022 Nov 15. doi: 10.1002/ijc.34342.
    PubMed     Abstract available
    
    
    
76. HANNIBAL CG, Baandrup L, Hertzum-Larsen R, Vang R, et al
    Risk of non-ovarian cancer in a nationwide-based study of nearly 5,000 women with borderline ovarian tumors in Denmark.
    Int J Cancer. 2022 Nov 10. doi: 10.1002/ijc.34354.
    PubMed     Abstract available
    
    
    
77. PARKER VL, Winter MC, Tidy JA, Hancock BW, et al
    PREDICT-GTN 1: Can we improve the FIGO scoring system in Gestational Trophoblastic Neoplasia?
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34352.
    PubMed     Abstract available
    
    
    October 2022
78. GIZAW M, Parkin DM, Stoter O, Korir A, et al
    Trends in the Incidence of Ovarian Cancer in sub-Saharan Africa.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34335.
    PubMed     Abstract available
    
    
    
79. SIVARS L, Palsdottir K, Crona Guterstam Y, Falconer H, et al
    The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors: A review.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34333.
    PubMed     Abstract available
    
    
    
80. VAN DER MEER R, Bakkers C, van Erning FN, Simkens LHJ, et al
    A propensity score matched analysis of oncological outcome after systemic therapy for stage IV colorectal cancer: Impact of synchronous ovarian metastases.
    Int J Cancer. 2022 Oct 17. doi: 10.1002/ijc.34325.
    PubMed     Abstract available
    
    
    
81. RING LL, Munk C, Galanakis M, Tota JE, et al
    Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019 - population impact of multi-cohort vaccination against human papillomavirus infection.
    Int J Cancer. 2022 Oct 17. doi: 10.1002/ijc.34328.
    PubMed     Abstract available
    
    
    
82. YAO J, Takenaga K, Koshikawa N, Kida Y, et al
    Anticancer effect of a pyrrole-imidazole polyamide-triphenylphosphonium conjugate selectively targeting a common mitochondrial DNA cancer risk variant in cervical cancer cells.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34319.
    PubMed     Abstract available
    
    
    
83. BAHAR-SHANY K, Barnabas GD, Deutsch L, Deutsch N, et al
    Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318.
    PubMed     Abstract available
    
    
    
84. RAKISLOVA N, Carreras-Dieguez N, Manzotti C, Saude O, et al
    Differential etiopathogenic features of vulvar squamous cell carcinomas in sub-Saharan Africa and Europe.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34314.
    PubMed     Abstract available
    
    
    
85. SAUVAGET C, Bazikamwe S, Lucas E, Ndayikengurukiye A, et al
    Evaluation of effectiveness, acceptability and safety of thermal ablation in the treatment of cervical neoplasia in Burundi.
    Int J Cancer. 2022;151:1120-1126.
    PubMed     Abstract available
    
    
    September 2022
86. ADEBAMOWO SN, Befano B, Cheung LC, Rodriguez AC, et al
    Different human papillomavirus types share early natural history transitions in immunocompetent women.
    Int J Cancer. 2022;151:920-929.
    PubMed     Abstract available
    
    
    
87. ZHONG GC, Zhu Q, Cai D, Hu JJ, et al
    Ultra-processed food consumption and the risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34290.
    PubMed     Abstract available
    
    
    
88. KAHESA C, Thomsen LT, Linde DS, Mchome B, et al
    Comparison of human papillomavirus (HPV)-based cervical cancer screening strategies in Tanzania among women with and without HIV.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34283.
    PubMed     Abstract available
    
    
    
89. LEHTINEN M, Pimenoff VN, Nedjai B, Louvanto K, et al
    Assessing the risk of cervical neoplasia in the post-HPV vaccination era.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34286.
    PubMed     Abstract available
    
    
    
90. SCHREIBERHUBER L, Herzog C, Vavourakis CD, Redl E, et al
    The WID(TM) -qEC test - performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers.
    Int J Cancer. 2022 Sep 2. doi: 10.1002/ijc.34275.
    PubMed     Abstract available
    
    
    August 2022
91. FRENSEMEIER K, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F, et al
    Dickkopf-1 expression is repressed by oncogenic human papillomaviruses (HPVs) and regulates the Cisplatin sensitivity of HPV-positive cancer cells in a JNK-dependent manner.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34250.
    PubMed     Abstract available
    
    
    
92. LI Y, Chen R, Yuan M, Wang D, et al
    One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing.
    Int J Cancer. 2022 Aug 13. doi: 10.1002/ijc.34241.
    PubMed     Abstract available
    
    
    
93. NORMAN I, Yilmaz E, Hjerpe A, Hortlund M, et al
    Atypical glandular cells and development of cervical cancer: Population-based cohort study.
    Int J Cancer. 2022 Aug 13. doi: 10.1002/ijc.34242.
    PubMed     Abstract available
    
    
    
94. SENGAYI-MUCHENGETI M, Singh E, Chen WC, Bradshaw D, et al
    Thirteen cancers associated with HIV infection in a Black South African cancer patient population (1995-2016).
    Int J Cancer. 2022 Aug 4. doi: 10.1002/ijc.34236.
    PubMed     Abstract available
    
    
    July 2022
95. GARGANO JW, McClung N, Lewis RM, Park IU, et al
    HPV type-specific trends in cervical precancers in the United States, 2008-2016.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34231.
    PubMed     Abstract available
    
    
    
96. BHATT A, Bhandoria G, Kepenekian V, Bakrin N, et al
    Comments on ' Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial'.
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34220.
    PubMed    
    
    
    
97. KOOLE SN, Schouten PC, van Driel WJ, Sonke GS, et al
    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial".
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34219.
    PubMed    
    
    
    
98. JOSHI S, Muwonge R, Kulkarni V, Mandolkar M, et al
    Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India.
    Int J Cancer. 2022 Jul 19. doi: 10.1002/ijc.34221.
    PubMed     Abstract available
    
    
    June 2022
99. YOON M, Lee HK, Park EY, Kim JH, et al
    Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study.
    Int J Cancer. 2022 Jun 25. doi: 10.1002/ijc.34190.
    PubMed     Abstract available
    
    
    
100. HUSBY A, Wohlfahrt J, Melbye M
     Pregnancy duration and ovarian cancer risk: a 50-year nationwide cohort study.
     Int J Cancer. 2022 Jun 24. doi: 10.1002/ijc.34192.
     PubMed     Abstract available
     
     
     
101. CAO H, Gong Y, Wang Y
     The prognostic impact of myosteatosis on overall survival in gynecological cancer patients: A meta-analysis and trial sequential analysis.
     Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34179.
     PubMed     Abstract available
     
     
     
102. BAANDRUP L, Galanakis M, Hannibal CG, Dehlendorff C, et al
     Long-term survival of non-localized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis - the Extreme study.
     Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34171.
     PubMed     Abstract available
     
     
     
103. AUVINEN E, Nieminen P, Pellinen J, Dillner J, et al
     HPV self-sampling with mRNA testing benefits routine screening.
     Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34170.
     PubMed     Abstract available
     
     
     
104. ATWAL A, Snowsill T, Dandy MC, Krum T, et al
     The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
     Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
     PubMed     Abstract available
     
     
     
105. TODISCO E, Gigli F, Ronchini C, Amato V, et al
     Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes.
     Int J Cancer. 2022 Jun 13. doi: 10.1002/ijc.34162.
     PubMed     Abstract available
     
     
     
106. SA JK, Kim J, Kang S, Kim SW, et al
     Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing; A Korean Gynecologic Oncology Group study (KGOG 3047).
     Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34150.
     PubMed     Abstract available
     
     
     
107. HAMPL M, Hesselink AT, Meijer CJLM, Denecke A, et al
     Evaluation of FAM19A4/miR124-2 methylation performance in the management of CIN3 diagnosed pregnant women.
     Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34153.
     PubMed     Abstract available
     
     
     
108. DESAI KT, Adepiti CA, Schiffman M, Egemen D, et al
     Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management.
     Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34151.
     PubMed     Abstract available
     
     
     May 2022
109. HARRIS HR, Guertin KA, Camacho TF, Johnson CE, et al
     Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium.
     Int J Cancer. 2022 May 28. doi: 10.1002/ijc.34141.
     PubMed     Abstract available
     
     
     
110. KOOLE SN, Schouten PC, Hauke J, Kluin RJC, et al
     Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial.
     Int J Cancer. 2022 May 18. doi: 10.1002/ijc.34124.
     PubMed     Abstract available
     
     
     
111. GIORGI ROSSI P, Ronco G, Mancuso P, Carozzi F, et al
     Performance of HPV E6/E7 mRNA Assay as Primary Screening Test. Results from the NTCC2 Trial.
     Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34120.
     PubMed     Abstract available
     
     
     
112. JAIN S, Nadeem N, Ulfenborg B, Makela M, et al
     Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
     Int J Cancer. 2022 May 9. doi: 10.1002/ijc.34111.
     PubMed     Abstract available
     
     
     
113. BURGER EA, Laprise JF, Sy S, Regan MC, et al
     Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting.
     Int J Cancer. 2022 May 5. doi: 10.1002/ijc.34054.
     PubMed     Abstract available
     
     
     
114. HURTADO-SALGADO E, Cardenas-Cardenas L, Salmeron J, Luna-Gordillo R, et al
     Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level.
     Int J Cancer. 2022;150:1422-1430.
     PubMed     Abstract available
     
     
     April 2022
115. ADCOCK R, Nedjai B, Lorincz A, Scibior-Bentkowska D, et al
     DNA methylation testing with S5 for triage of high-risk HPV positive women.
     Int J Cancer. 2022 Apr 27. doi: 10.1002/ijc.34050.
     PubMed     Abstract available
     
     
     
116. GOTTSCHLICH A, Gondara L, Smith LW, Cook D, et al
     HPV-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV FOr CervicAL Cancer (HPV FOCAL) trial.
     Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34039.
     PubMed     Abstract available
     
     
     
117. ZHANG L, Zhao X, Hu S, Chen S, et al
     Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study.
     Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34041.
     PubMed     Abstract available
     
     
     
118. ROMANI C, Capoferri D, Reijnen C, Lonardi S, et al
     L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
     Int J Cancer. 2022 Apr 16. doi: 10.1002/ijc.34035.
     PubMed     Abstract available
     
     
     
119. STANCZUK GA, Currie H, Forson W, Baxter G, et al
     Self-sampling as the principal modality for population based cervical screening: Five-year follow-up of the PaVDaG study.
     Int J Cancer. 2022;150:1350-1356.
     PubMed     Abstract available
     
     
     
120. SAHASRABUDDHE VV, Castle PE, Schiffman M, Wentzensen N, et al
     Reply to: Comments on 'Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening'.
     Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34013.
     PubMed    
     
     
     
121. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
     Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
     Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
     PubMed     Abstract available
     
     
     
122. BRENTNALL AR, Rebolj M
     Comments on: "Meta-analysis of agreement/concordance statistics in studies comparing self-versus clinician-collected samples for HPV testing in cervical cancer screening".
     Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34014.
     PubMed    
     
     
     March 2022
123. ZHAO Y, Gao YT, Zhang X, Rockwood AL, et al
     Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never-smoking women.
     Int J Cancer. 2022 Mar 26. doi: 10.1002/ijc.34005.
     PubMed     Abstract available
     
     
     
124. CABASAG CJ, Fagan PJ, Ferlay J, Vignat J, et al
     Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020.
     Int J Cancer. 2022 Mar 23. doi: 10.1002/ijc.34002.
     PubMed     Abstract available
     
     
     February 2022
125. LUPIA M, Melocchi V, Bizzaro F, Lo Riso P, et al
     Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.
     Int J Cancer. 2022 Feb 26. doi: 10.1002/ijc.33983.
     PubMed     Abstract available
     
     
     
126. ARBYN M, Castle PE, Schiffman M, Wentzensen N, et al
     Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening.
     Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33967.
     PubMed     Abstract available
     
     
     January 2022
127. YAN X, Zhao W, Wei J, Yao Y, et al
     A serum lipidomics study for the identification of specific biomarkers for endometrial polyps to distinguish them from endometrial cancer or hyperplasia.
     Int J Cancer. 2022 Jan 25. doi: 10.1002/ijc.33943.
     PubMed     Abstract available
     
     
     
128. MAILLIEZ A, Pigny P, Bogart E, Keller L, et al
     Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.
     Int J Cancer. 2022 Jan 17. doi: 10.1002/ijc.33933.
     PubMed     Abstract available
     
     
     
129. VAN DER WATT PJ, Okpara MO, Wishart A, Parker MI, et al
     Nuclear transport proteins are secreted by cancer cells and identified as potential novel cancer biomarkers.
     Int J Cancer. 2022;150:347-361.
     PubMed     Abstract available
     
     
     
130. YAGI A, Ueda Y, Ikeda S, Miyoshi A, et al
     Improved long-term survival of corpus cancer in Japan: A 40-year population-based analysis.
     Int J Cancer. 2022;150:232-242.
     PubMed     Abstract available
     
     
     December 2021
131. PARK B
     Changes in weight and waist circumference during menopausal transition and postmenopausal breast cancer risk.
     Int J Cancer. 2021 Dec 18. doi: 10.1002/ijc.33906.
     PubMed     Abstract available
     
     
     
132. HERMENS M, van Altena AM, van der Aa M, Bulten J, et al
     Endometrial cancer prognosis in women with endometriosis and adenomyosis. A retrospective nationwide cohort study of 40,840 women.
     Int J Cancer. 2021 Dec 18. doi: 10.1002/ijc.33907.
     PubMed     Abstract available
     
     
     
133. HORTLUND M, Muhr LSA, Lagheden C, Hjerpe A, et al
     Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program.
     Int J Cancer. 2021;149:2083-2090.
     PubMed     Abstract available
     
     
     
134. REBOLJ M, Mathews CS, Pesola F, Castanon A, et al
     Acceleration of Cervical Cancer Diagnosis with Human Papillomavirus Testing Below Age 30: Observational Study.
     Int J Cancer. 2021 Dec 12. doi: 10.1002/ijc.33900.
     PubMed     Abstract available
     
     
     
135. PERSSON MS, Yin W, Doring N, Risnes K, et al
     Gestational age and cancer risk up to young adulthood in Swedish population born 1974-2013: a population-based cohort study.
     Int J Cancer. 2021 Dec 2. doi: 10.1002/ijc.33886.
     PubMed     Abstract available
     
     
     November 2021
136. DESAI KT, Befano B, Xue Z, Kelly H, et al
     The development of "Automated Visual Evaluation" for cervical cancer screening: The promise and challenges in adapting deep-learning for clinical testing.
     Int J Cancer. 2021 Nov 20. doi: 10.1002/ijc.33879.
     PubMed     Abstract available
     
     
     
137. KIM DS, Ahn HS, Kim HJ
     Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database.
     Int J Cancer. 2021 Nov 9. doi: 10.1002/ijc.33869.
     PubMed     Abstract available
     
     
     
138. BERGHUIS AY, Pijnenborg JFA, Boltje TJ, Pijnenborg JMA, et al
     Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatment.
     Int J Cancer. 2021 Nov 6. doi: 10.1002/ijc.33866.
     PubMed     Abstract available
     
     
     
139. SPENCER JC, Campos NG, Burger EA, Sy S, et al
     Potential Effectiveness of a Therapeutic HPV Intervention Campaign in Uganda.
     Int J Cancer. 2021 Nov 6. doi: 10.1002/ijc.33867.
     PubMed     Abstract available
     
     
     October 2021
140. ISLAM S, Dutta P, Sahay O, Gopalakrishnan K, et al
     Feedback-regulated transcriptional repression of FBXO31 by c-Myc triggers ovarian cancer tumorigenesis.
     Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33854.
     PubMed     Abstract available
     
     
     
141. RAVEGNINI G, Gorini F, De Crescenzo E, De Leo A, et al
     Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review.
     Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33857.
     PubMed     Abstract available
     
     
     
142. GUSTINUCCI D, Benevolo M, Cesarini E, Mancuso P, et al
     Accuracy of Different Triage Strategies for HPV Positivity in an Italian Screening Population.
     Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33858.
     PubMed     Abstract available
     
     
     
143. HARPER DM, Rozek LS
     Cervical cancer prevention becomes more efficient.
     Int J Cancer. 2021 Oct 19. doi: 10.1002/ijc.33851.
     PubMed    
     
     
     
144. PEDERSEN K, Portnoy A, Sy S, Hansen BT, et al
     Switching clinic-based cervical cancer screening programs to HPV self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
     Int J Cancer. 2021 Oct 18. doi: 10.1002/ijc.33850.
     PubMed     Abstract available
     
     
     
145. SKOLD C, Koliadi A, Enblad G, Stalberg K, et al
     Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
     Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33844.
     PubMed     Abstract available
     
     
     
146. IBRAHIM KHALIL A, Mpunga T, Wei F, Baussano I, et al
     Age-specific burden of cervical cancer associated with HIV: a global analysis with a focus on sub-Saharan Africa.
     Int J Cancer. 2021 Oct 9. doi: 10.1002/ijc.33841.
     PubMed     Abstract available
     
     
     September 2021
147. BANILA C, Lorincz AT, Scibior-Bentkowska D, Clifford GM, et al
     Clinical performance of methylation as a biomarker for cervical carcinoma-in-situ and cancer diagnosis: a worldwide study.
     Int J Cancer. 2021 Sep 25. doi: 10.1002/ijc.33815.
     PubMed     Abstract available
     
     
     
148. VERHOEF L, Bleeker MCG, Polman N, Steenbergen RDM, et al
     Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: results from a Dutch primary HPV-based screening cohort.
     Int J Cancer. 2021 Sep 24. doi: 10.1002/ijc.33820.
     PubMed     Abstract available
     
     
     
149. WRIGHT TC JR, Stoler MH, Ranger-Moore J, Fang Q, et al
     Clinical Validation of p16/Ki-67 Dual-Stained Cytology Triage of HPV-Positive Women - Results from the IMPACT Trial.
     Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33812.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.